GO:0032693 negative regulation of interleukin-10 production: Immune Suppression Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032693 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-10 (IL-10) production.
• IL-10 is a pleiotropic anti-inflammatory cytokine, and its negative regulation is critical for balancing immune activation and tolerance.
• Key negative regulators include pyruvate dehydrogenase kinase (PDK), which restricts IL-10 production in macrophages.
• Dysregulated negative regulation of IL-10 production contributes to autoimmune diseases, chronic infections, and cancer [1,3,4].
• Experimental models such as knockout mice, point-mutant knock-in cells, and CRISPR screens are essential to dissect this pathway [2,5].
• Understanding GO:0032693 informs therapeutic strategies targeting IL-10 in inflammatory and neoplastic disorders [1,6].
Description
Interleukin-10 (IL-10) is a master anti-inflammatory cytokine that limits excessive immune responses and maintains tissue homeostasis. The biological process termed negative regulation of interleukin-10 production (GO:0032693) encompasses all molecular events that decrease the synthesis or secretion of IL-10. This regulation is vital because unchecked IL-10 can lead to immunosuppression and cancer progression, while insufficient IL-10 contributes to autoimmunity and chronic inflammation [1,3]. Researchers study GO:0032693 to identify checkpoints that can be therapeutically modulated in diseases such as rheumatoid arthritis, inflammatory bowel disease, and melanoma [1,4]. Recent work has uncovered diverse negative regulators, including metabolic enzymes and signaling molecules, that fine-tune IL-10 output in macrophages, B cells, and microglia [2,5,7]. Understanding these mechanisms at the genetic and cellular level is essential for developing targeted immunotherapies [1,8].
negative regulation of interleukin-10 production At A Glance
| GO ID | GO:0032693 |
|---|---|
| GO term | negative regulation of interleukin-10 production |
| Ontology | biological_process |
| Synonym | negative regulation of IL-10 production; inhibition of interleukin-10 production; downregulation of interleukin-10 production |
| Major function | Reduces the frequency, rate, or extent of IL-10 production, thereby modulating immune responses. |
| Related processes | Regulation of cytokine production, inflammatory response, immune tolerance. |
| Key regulators | PDK, histaminergic signaling, autocrine/exocrine factors [2,5,6]. |
| Disease relevance | Autoimmunity, cancer, neurodegeneration, chronic infections [1,3,4]. |
What Is GO:0032693?
Negative regulation of interleukin-10 production (GO:0032693) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-10 production. This includes inhibition of IL-10 gene transcription, mRNA stability, protein translation, and secretion. The term is a biological process and is distinct from positive regulation of IL-10 production.
Why Is negative regulation of interleukin-10 production Important in Cell Biology?
Negative regulation of IL-10 production is crucial for preventing excessive immunosuppression and for maintaining a balanced immune response. Dysregulation of this process is implicated in a wide range of human diseases, from autoimmune disorders to cancer and neurodegenerative conditions [1,3,5]. Understanding how IL-10 production is negatively regulated can reveal new therapeutic targets and biomarkers [1,2].
• Prevents immunosuppression that could lead to chronic infections or cancer.
• Limits tissue damage by controlling excessive anti-inflammatory signals.
• Modulates autoimmune disease activity, including arthritis and colitis [3,4].
• Influences tumor microenvironment and response to immunotherapy.
• Regulates neuroinflammation in Parkinson's disease and other neurodegenerative disorders.
• Controls B cell-mediated immune regulation and microbiota homeostasis.
• Provides targets for drug development in inflammatory diseases [2,6].
• Helps understand macrophage polarization and metabolic reprogramming [2,8].
What Happens During negative regulation of interleukin-10 production?
Initiation of negative regulatory signals
In simple terms: The process starts when a cell receives signals that tell it to reduce IL-10 production.
Negative regulation of IL-10 production is initiated by extracellular or intracellular cues, such as metabolic stress, histamine, or autocrine factors [2,5,6]. These signals activate specific transcription factors or signaling cascades that ultimately suppress IL-10 gene expression.
Transcriptional repression of IL10
In simple terms: The cell turns down the IL-10 gene by blocking its transcription.
Transcriptional repression involves the recruitment of repressors or the inhibition of activators at the IL10 promoter. For example, pyruvate dehydrogenase kinase (PDK) has been shown to negatively regulate IL-10 production in macrophages, partly through metabolic and transcriptional mechanisms.
Post-transcriptional and translational control
In simple terms: Even if some IL-10 mRNA is made, the cell can prevent it from becoming protein.
Negative regulation can occur post-transcriptionally by reducing IL-10 mRNA stability or blocking translation. MicroRNAs and RNA-binding proteins are known to target the 3' untranslated region of IL10 mRNA, leading to decreased protein output.
Inhibition of IL-10 secretion
In simple terms: The cell can also stop IL-10 from being released outside.
Secretion of IL-10 can be negatively regulated at the level of vesicular trafficking or by factors that retain IL-10 intracellularly. This ensures that even if IL-10 is synthesized, it does not reach the extracellular space to exert its anti-inflammatory effects.
Feedback and crosstalk with other pathways
In simple terms: The process is connected to other immune signals to keep everything balanced.
Negative regulation of IL-10 production is integrated with other signaling pathways, such as those involving pro-inflammatory cytokines or pattern recognition receptors [1,6]. This crosstalk ensures that IL-10 levels are appropriately tuned to the immune context [1,8].
Key Genes Involved in GO:0032693 negative regulation of interleukin-10 production
The following genes and proteins have been experimentally implicated in the negative regulation of interleukin-10 production.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDK1 | Pyruvate dehydrogenase kinase 1; negatively regulates IL-10 production in macrophages | Metabolic control of IL-10; target for inflammatory diseases |
| HRH1 | Histamine receptor H1; signaling can promote IL-10, but negative regulators downstream exist | Microglial histaminergic signaling in Parkinson's disease |
| IL10 | The gene encoding interleukin-10; its production is the target of negative regulation | Core cytokine in immune tolerance and autoimmunity |
| IL10RA | IL-10 receptor alpha; feedback can influence IL-10 production | IL-10 signaling feedback |
| IL10RB | IL-10 receptor beta; part of the IL-10 receptor complex | IL-10 signaling feedback |
| STAT3 | Signal transducer and activator of transcription 3; can both promote and be negatively regulated | Transcription factor in IL-10 regulation |
| NFKB1 | Nuclear factor kappa B subunit 1; often suppresses IL-10 when activated | Inflammatory signaling crosstalk |
| MAPK1 | Mitogen-activated protein kinase 1; involved in negative regulation of IL-10 | Kinase pathways in macrophages |
| MAPK3 | Mitogen-activated protein kinase 3; involved in negative regulation of IL-10 | Kinase pathways in macrophages |
| AKT1 | AKT serine/threonine kinase 1; can negatively regulate IL-10 production | Metabolic and survival signaling |
| MTOR | Mechanistic target of rapamycin kinase; integrates metabolic signals to suppress IL-10 | mTOR pathway in immune cells |
| HIF1A | Hypoxia inducible factor 1 subunit alpha; can influence IL-10 production | Hypoxia and metabolism |
| PRKAA1 | Protein kinase AMP-activated catalytic subunit alpha 1; energy sensor that can suppress IL-10 | AMPK signaling |
| SOCS1 | Suppressor of cytokine signaling 1; negative feedback on cytokine production | Cytokine signaling |
| SOCS3 | Suppressor of cytokine signaling 3; negative feedback on cytokine production | Cytokine signaling |
| PTPN22 | Protein tyrosine phosphatase non-receptor type 22; may modulate IL-10 production | Autoimmunity genetics |
| TNF | Tumor necrosis factor; pro-inflammatory cytokine that can suppress IL-10 | Inflammatory crosstalk |
| IL6 | Interleukin 6; can negatively regulate IL-10 in certain contexts | Inflammatory crosstalk |
How Is negative regulation of interleukin-10 production Regulated?
Negative regulation of IL-10 production is controlled by a network of signaling pathways, including mTOR, AMPK, and MAPK cascades. Metabolic enzymes such as pyruvate dehydrogenase kinase (PDK) act as key negative regulators by linking cellular metabolism to IL-10 transcription. Additionally, autocrine and exocrine factors, such as those induced by Borrelia burgdorferi lipoproteins, can modulate IL-10 production in monocytes. Histaminergic signaling in microglia has been shown to promote IL-10 production, implying that negative regulators exist to counterbalance this effect. The process is also influenced by B cell receptor signaling and microbiota-derived signals.
negative regulation of interleukin-10 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDK1 | Inflammatory diseases, cancer | Knockout mice, macrophage-specific deletion |
| IL10 | Autoimmunity, inflammatory bowel disease | IL-10 reporter mice, CRISPR knock-in |
| HRH1 | Parkinson's disease | Microglial-specific knockout, histamine treatment |
| SOCS1 | Autoimmunity, cytokine storm | Knockout mice, overexpression cell lines |
| PTPN22 | Rheumatoid arthritis, type 1 diabetes | Point-mutation knock-in mice |
Autoimmune and Inflammatory Diseases
Inadequate negative regulation of IL-10 production can lead to excessive IL-10, which suppresses protective immunity and may exacerbate autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease [1,3]. Conversely, overactive negative regulation can reduce IL-10 and promote inflammation. Regulatory plasma cells and B cells are key sources of IL-10, and their dysregulation is linked to autoimmunity [3,4].
Cancer
Tumor cells often exploit IL-10 to evade immune surveillance. Negative regulators of IL-10 production, such as PDK, may be targeted to reduce IL-10 in the tumor microenvironment and enhance anti-tumor immunity [1,2]. Understanding GO:0032693 is therefore relevant for cancer immunotherapy.
Neurodegeneration
In Parkinson's disease, microglial histaminergic signaling promotes IL-10 production and ameliorates motor dysfunction, suggesting that negative regulators of IL-10 could worsen neurodegeneration. Modulating GO:0032693 may offer therapeutic avenues for neuroinflammatory diseases.
Infectious Diseases
Pathogens such as Borrelia burgdorferi can modulate IL-10 production in host cells, and negative regulation of IL-10 is important for controlling infection while limiting immunopathology. Dysregulation can lead to chronic infections.
From negative regulation of interleukin-10 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IL-10 production? | CRISPR knockout in macrophages, followed by IL-10 ELISA |
| What is the effect of a specific point mutation in a regulator? | Point-mutation knock-in via CRISPR |
| How does a regulator affect IL-10 transcription? | Knock-in of tagged transcription factor, ChIP-seq |
| Can overexpression of a negative regulator reduce IL-10 in vivo? | Transgenic overexpression mice |
| Which genes are essential for negative regulation of IL-10? | Genome-wide CRISPR library screening |
| How does metabolic signaling impact IL-10 production? | Metabolic flux analysis in knockout cells |
How to Study the negative regulation of interleukin-10 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Genes that negatively regulate IL-10 | Discovery of novel regulators |
| RNA-seq | Transcriptional changes in IL10 and related genes | Pathway analysis |
| ELISA | IL-10 protein concentration | Validation of negative regulation |
| Flow cytometry | Intracellular IL-10 in single cells | Immune cell subset analysis |
| Western blot | Protein levels of signaling molecules | Mechanistic studies |
| Phosphoproteomics | Kinase activity changes | Signaling pathway dissection |
| ChIP-seq | Transcription factor binding at IL10 locus | Transcriptional regulation |
| Metabolic assays | Cellular metabolism (e.g., glycolysis, OXPHOS) | Link to PDK and mTOR |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify genes whose loss increases IL-10 production, revealing negative regulators. This approach is powerful for unbiased discovery of components in GO:0032693.
RNA Sequencing and Transcriptomics
RNA-seq of cells with perturbed candidate genes can show changes in IL10 mRNA levels, indicating transcriptional regulation. It also reveals downstream pathways affected by negative regulators.
Cytokine Profiling by ELISA and Flow Cytometry
Measuring IL-10 protein secretion in culture supernatants or intracellularly by flow cytometry is a direct way to assess negative regulation [2,6]. This is often the primary readout in functional studies.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can identify signaling changes and post-translational modifications that mediate negative regulation of IL-10 production. Phosphoproteomics is particularly useful for kinase pathways.
How CRISPR Can Be Used to Study GO:0032693 negative regulation of interleukin-10 production
Knockout
CRISPR knockout of candidate negative regulators (e.g., PDK1) in macrophages or other immune cells can confirm their role in suppressing IL-10 production. Knockout models are essential for loss-of-function studies in GO:0032693.
Point Mutation
Introducing specific point mutations in genes such as SOCS1 or PTPN22 can mimic human disease variants and reveal their impact on IL-10 regulation. This is useful for studying kinase domains or binding sites.
Knock-in
Knock-in of reporter genes (e.g., IL-10-GFP) or tagged proteins allows real-time tracking of IL-10 production and regulation. It also enables precise modification of regulatory elements.
Overexpression
Overexpression of a suspected negative regulator can reduce IL-10 production, providing gain-of-function evidence. This complements knockout studies and helps establish causality.
How EDITGENE Supports negative regulation of interleukin-10 production Research
Researchers studying negative regulation of interleukin-10 production-related genes often need to determine whether a candidate gene is causally involved in suppressing IL-10, and what molecular mechanism it uses. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-10 production research.
Frequently Asked Questions About negative regulation of interleukin-10 production
What is negative regulation of interleukin-10 production?
It is any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-10 production, as defined by GO:0032693.
What genes are involved in negative regulation of IL-10 production?
Key genes include PDK1, SOCS1, SOCS3, PTPN22, and various kinases such as MAPK1 and AKT1 [1,2].
How is IL-10 production negatively regulated in macrophages?
Macrophages use metabolic enzymes like PDK and signaling pathways such as mTOR and AMPK to suppress IL-10 production.
What diseases are associated with dysregulated negative regulation of IL-10?
Autoimmune diseases, cancer, neurodegenerative disorders like Parkinson's disease, and chronic infections [1,3,5,6].
What is the GO ID for negative regulation of interleukin-10 production?
The GO ID is GO:0032693.
How can I study negative regulation of IL-10 production using CRISPR?
CRISPR knockout, point mutation, knock-in reporters, and overexpression models can be used to dissect the pathway [1,2].
What are the synonyms for GO:0032693?
Synonyms include negative regulation of IL-10 production, inhibition of interleukin-10 production, and downregulation of interleukin-10 production.
Which immune cells produce IL-10 and how is it negatively regulated?
Macrophages, B cells, and microglia produce IL-10; negative regulation occurs via transcriptional, post-transcriptional, and secretory mechanisms [1,2,5,7].
What experimental models are used to study negative regulation of IL-10?
Knockout mice, CRISPR-edited cell lines, reporter mice, and genome-wide screens are commonly used [1,2,5].
Why is negative regulation of IL-10 important for immunotherapy?
It helps prevent immunosuppression in tumors and can be targeted to enhance anti-tumor immunity [1,2].
Conclusion
Negative regulation of interleukin-10 production (GO:0032693) is a critical biological process that fine-tunes immune responses to prevent excessive immunosuppression or inflammation. Its dysregulation is linked to autoimmunity, cancer, and neurodegeneration, making it a promising therapeutic target [1,3,5]. Advances in CRISPR-based models and screening technologies are rapidly uncovering the molecular players involved, offering new opportunities for drug discovery [2,8]. Continued research into this process will deepen our understanding of immune homeostasis and disease pathogenesis.
References
- 1. Rutz S et al.. 2016. Regulation of Interleukin-10 Expression.. Adv Exp Med Biol 941:89-116 PMID: 27734410
- 2. Na YR et al.. 2020. Pyruvate dehydrogenase kinase is a negative regulator of interleukin-10 production in macrophages.. J Mol Cell Biol 12(7):543-555 PMID: 31900478
- 3. Fillatreau S. 2015. Regulatory plasma cells.. Curr Opin Pharmacol 23:1-5 PMID: 25978519
- 4. Hilgenberg E et al.. 2014. Interleukin-10-producing B cells and the regulation of immunity.. Curr Top Microbiol Immunol 380:69-92 PMID: 25004814
- 5. Wang Y et al.. 2025. Microglial Histaminergic Signaling Promotes Interleukin-10 Production and Ameliorates Motor Dysfunction in Parkinson's Disease.. Aging Dis 17(3):1633-1654 PMID: 40423636
- 6. Giambartolomei GH et al.. 2002. Autocrine and exocrine regulation of interleukin-10 production in THP-1 cells stimulated with Borrelia burgdorferi lipoproteins.. Infect Immun 70(4):1881-8 PMID: 11895951
- 7. Gu Q et al.. 2024. Intestinal newborn regulatory B cell antibodies modulate microbiota communities.. Cell Host Microbe 32(10):1787-1804.e9 PMID: 39243760
- 8. Figueiredo AS et al.. 2009. Modelling and simulating interleukin-10 production and regulation by macrophages after stimulation with an immunomodulator of parasitic nematodes.. FEBS J 276(13):3454-69 PMID: 19456864
